Use of Orphan Drug Designation for Acute-Phase Spinal Cord Injury
A regulatory strategy to accelerate the marketing approval application for a medicinal product targeting the acute phase of spinal cord injury by leveraging development cost subsidies and priority review available under orphan drug designation.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.